Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PGNX

Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis

Progenics Pharmaceuticals logo

About Progenics Pharmaceuticals Stock (NASDAQ:PGNX)

Advanced Chart

Key Stats

Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume
34.93 million shs
Average Volume
1.16 million shs
Market Capitalization
$355.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PGNX Stock News Headlines

PGNX_old Historical Data
Investing in Pharmaceutical Stocks
Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
I've Got an Options Bandage for a Sick Economy
See More Headlines

PGNX Stock Analysis - Frequently Asked Questions

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Caterpillar (CAT), Exelixis (EXEL), IMAX (IMAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Citius Pharmaceuticals (CTXR).

Company Calendar

Last Earnings
5/07/2020
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PGNX
CIK
835887
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.55 million
Net Margins
-180.28%
Pretax Margin
N/A
Return on Equity
-129.46%
Return on Assets
-53.23%

Debt

Debt-to-Equity Ratio
0.99
Current Ratio
2.12
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$34.99 million
Price / Sales
10.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
7.59

Miscellaneous

Outstanding Shares
86,597,000
Free Float
N/A
Market Cap
$355.05 million
Optionable
Optionable
Beta
1.89
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:PGNX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners